Compare KXIN & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KXIN | MBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.7M |
| IPO Year | N/A | N/A |
| Metric | KXIN | MBIO |
|---|---|---|
| Price | $4.61 | $1.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 98.4K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $95,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.94 | $0.89 |
| 52 Week High | $75.00 | $21.95 |
| Indicator | KXIN | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 39.49 |
| Support Level | $3.32 | $1.21 |
| Resistance Level | $5.40 | $1.31 |
| Average True Range (ATR) | 0.85 | 0.09 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 78.25 | 0.03 |
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.